Danske Bank A/S Biogen Inc. Transaction History

Danske Bank A/S

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 19, 2025	BUY	$122.68 - $148.84 $5.49 Million - $6.65 Million	44,710 New	44,710 $6.26 Million
Q2 2025 Dec 18, 2025	SELL	$113.38 - $135.49 $967,358 - $1.16 Million	-8,532 Reduced 13.35%	55,396 $6.96 Million
Q1 2025 Dec 18, 2025	BUY	$133.43 - $153.27 $2.56 Million - $2.95 Million	19,218 Added 42.98%	63,928 $8.75 Million

1,077

131M

3.77M

2.31M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $24.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

Stay updated on Danske Bank A/S with notifications on news.